Anavex shares recorded their steepest drop in nearly two years as its Alzheimer drug, blarcamesine, completed Oral Explanation Week at the EMA. The step signals regulators still have unresolved questions late in the review. Investors are watching for a CHMP update after earlier data suggested the drug may slow cognitive decline.